Free Trial
NASDAQ:FBRX

Forte Biosciences Q2 2025 Earnings Report

Forte Biosciences logo
$11.07 +0.02 (+0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$11.09 +0.02 (+0.18%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences EPS Results

Actual EPS
-$0.96
Consensus EPS
-$1.21
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

Forte Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Forte Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Forte Biosciences' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Forte Biosciences Earnings Headlines

What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.tc pixel
See More Forte Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email.

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

View Forte Biosciences Profile

More Earnings Resources from MarketBeat